Session » Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM

Abstract Number: 1159

Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database

10:30AM-12:30PM

Abstract Number: 1144

Autoantibody and Radiological Profiles as Prognostic Indicators in Idiopathic Inflammatory Myopathies: Insights into Mortality and Interstitial Lung Disease Development

10:30AM-12:30PM

Abstract Number: 1149

Cause-Specific Proportionate Mortality Trends in Idiopathic Inflammatory Myopathies

10:30AM-12:30PM

Abstract Number: 1163

Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population

10:30AM-12:30PM

Abstract Number: 1166

Characteristics, Treatments, and Outcomes of Patients with Dermatomyositis from Two Large, Nationwide US Cohorts

10:30AM-12:30PM

Abstract Number: 1161

Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity

10:30AM-12:30PM

Abstract Number: 1151

Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy

10:30AM-12:30PM

Abstract Number: 1145

Clinico-Immunological Profile and Treatment Outcomes of Clinically Significant Diaphragmatic Weakness in Patients with Idiopathic Inflammatory Myopathies: Results from the Largest Single-Center Cohort of 16 Cases

10:30AM-12:30PM

Abstract Number: 1154

Comparative Transcriptome Analysis of Murine Model and Human Samples in Anti-Melanoma Differentiation Associated Gene 5 Antibody-positive Rapidly Progressive Interstitial Lung Disease

10:30AM-12:30PM

Abstract Number: 1139

Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes

10:30AM-12:30PM

Abstract Number: 1170

Computer Aided Lung Informatics, HRCT and PFT in Patients with Interstitial Lung Disease in Idiopathic Inflammatory Myopathies

10:30AM-12:30PM

Abstract Number: 1167

Construction of a Refractory Myositis Predictive Index (ReMPI) in a Cohort of Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM

Abstract Number: 1141

Defining a Novel Type of Myositis: Immune Mediated Megaconial Myopathy (IMMM)

10:30AM-12:30PM

Abstract Number: 1142

Disease Trajectory in anti-MDA5 Dermatomyositis Patients Presented with Different Stage of Interstitial Lung Disease

10:30AM-12:30PM

Abstract Number: 1165

Dysregulation of Peripheral Blood B-cells Is Associated with Myocarditis in Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM

Abstract Number: 1169

Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study

10:30AM-12:30PM

Abstract Number: 1143

Epidemiology and Spectrum of Idiopathic Inflammatory Myopathies in Individuals of Sub-Saharan Ancestry: Data from the Tertiary Care Center of the Caribbean Island of Martinique

10:30AM-12:30PM

Abstract Number: 1162

Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom

10:30AM-12:30PM

Abstract Number: 1147

Evaluation of Adverse Pregnancy Outcomes in Patients with Inflammatory Myopathies and Ro Positivity

10:30AM-12:30PM

Abstract Number: 1146

Impact of COVID-19 on Myositis Testing Trends

10:30AM-12:30PM

Abstract Number: 1168

Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan

10:30AM-12:30PM

Abstract Number: 1150

Increased ISG15 Expression in Peripheral Blood from Patients with Positive Dermatomyositis Related Specific Autoantibodies

10:30AM-12:30PM

Abstract Number: 1153

Increased Prevalence of Myositis Specific and Associated Autoantibodies in Patients with Interstitial Lung Disease of Unknown Etiology

10:30AM-12:30PM

Abstract Number: 1164

IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients

10:30AM-12:30PM

Abstract Number: 1158

Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients

10:30AM-12:30PM

Abstract Number: 1152

Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets

10:30AM-12:30PM

Abstract Number: 1156

Prevalence and Impact of Fibromyalgia in Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM

Abstract Number: 1140

Pulmonary Hypertension in Hospitalized Patients with Dermatomyositis & Polymyositis: A Nationwide Cohort Analysis

10:30AM-12:30PM

Abstract Number: 1157

Reduced Statin Use in Patients with Autoimmune Myopathies and Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Non-Inflammatory Diseases

10:30AM-12:30PM

Abstract Number: 1160

Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness

10:30AM-12:30PM

Abstract Number: 1148

Simplified Cutaneous Dermatomyositis Disease Area and Severity Index Activity Scores for Cutaneous Dermatomyositis

10:30AM-12:30PM

Abstract Number: 1155

Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening